Novo Nordisk Unveils Promising Research on Bone Health During Weight Loss at ObesityWeek 2026

Novo Nordisk's Recent Findings on Bone Health



At the recent ObesityWeek 2026, Novo Nordisk unveiled compelling preclinical and clinical data suggesting that the activation of amylin and calcitonin receptors plays a crucial role in maintaining bone health during weight loss. As weight reduction through various methods—be it diet, medication, or surgery—can often lead to bone loss and increasing fracture risk, this groundbreaking research marks a significant stride forward in addressing the associated challenges.

Novo's research primarily focused on its investigational medicines: CagriSema, cagrilintide, and zenagamtide, revealing that these treatments lead to reduced bone loss in preclinical models, particularly those mimicking postmenopausal bone health. The findings suggest a dual approach, leveraging both amylin and calcitonin receptor activation, crucial for combating bone density loss during weight management. Martin Holst Lange, Novo's Chief Scientific Officer, noted that understanding the molecular biology behind these receptors can pave the way for better treatment outcomes in individuals undergoing weight loss.

Key Findings from the Research



1. Preclinical Model Insights:
In a study simulating postmenopausal bone loss, CagriSema and cagrilintide demonstrated a significant reduction in bone loss. Over an eight-week period, cagrilintide showed a 43% increase in trabecular bone volume and CagriSema demonstrated a 40% increase compared to control groups.

2. Human Studies:
Initial human studies indicated that cagrilintide and zenagamtide successfully suppressed CTX-I, a biomarker associated with bone breakdown, while NN1213—a selective amylin receptor agonist—did not show the same effect. This difference highlights the potential importance of activating the calcitonin receptor alongside the amylin receptor in maintaining bone integrity.

3. Post Hoc Analysis of REDEFINE 1 Trial:
An analysis of the REDEFINE 1 trial revealed that despite expected decreases in bone mineral density (BMD) in participants receiving CagriSema due to weight loss, these levels remained within the normal range for age and sex. Moreover, indicators of both bone formation and breakdown were assessed, underscoring the complexity of bone health during significant weight loss.

Clinical Implications and Future Directions



Dr. Marco Ponzetti, who conducted the research, emphasized the necessity for further investigations to verify these findings and explore their clinical significance. The observed receptor activity provides early optimism regarding the possible integration of these treatments into clinical practice to protect bone health for patients undergoing weight loss.

As Novo Nordisk seeks regulatory approval for CagriSema, which combines a dual amylin and calcitonin receptor agonist with a GLP-1 receptor agonist, their efforts highlight a commitment to safely manage obesity and its repercussions on bone health. The growing evidence supporting the role of receptor activation in bone preservation underscores the potential for developing innovative treatment strategies aimed at not just weight loss, but comprehensive wellness.

Conclusion



The research presented at ObesityWeek 2026 by Novo Nordisk could fundamentally alter the landscape of obesity treatment paradigms, especially considering the pervasive issue of bone density loss associated with weight management strategies. The preliminary data serves as a hopeful precursor for ongoing clinical trials and therapeutic advancements aimed at fostering not only effective weight loss but also enduring bone health for at-risk populations.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.